[ad_1]
press release
AB Science will host a live webcast on Monday, March 4, 2024 from 6:30pm to 7:30pm CET
Paris, February 29, 2024, 11:30 a.m. CET
AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Monday, March 4, 2024 from 6:30 PM to 7:30 PM (CET).
The topic of this live webcast is to provide current status and perspective on the following topics:
- Conditional approval of masitinib in ALS by EMA and Health Canada
- partnership strategy
- masitinib platform clinical development program
- Microtubulin platform development program
- intellectual property
There will be a question and answer session after the presentation.
Login details for this live webcast will be provided later.
About AB Science
AB Science, founded in 2001, is a pharmaceutical company specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs), a type of target protein whose actions are key in intracellular signaling pathways. . Our programs target only diseases with high unmet medical need, diseases that are often fatal with short survival times, or diseases that are rare or refractory to previous treatments.
AB Science has developed a unique portfolio of molecules, and its lead compound, masitinib, is already registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases, and viral diseases. It has been. The company is headquartered in Paris, France and listed on Euronext Paris (ticker: AB).
For more information, please visit the AB Science website.
www.ab-science.com.
Forward-Looking Statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates and the underlying assumptions, financial results, events, operations, future services, product developments, and projects, objectives, intentions and expectations regarding their potential or future performance. Contains descriptions.
These forward-looking statements often refer to the words “expect,” “anticipate,” “believe,” “intend,” “estimate,” or “plan,” or other similar terminology. can be identified by Although AB Science believes that these forward-looking statements are reasonable, investors should note that these forward-looking statements involve a number of risks and conditions that are difficult to predict and generally beyond AB Science’s control. Please note that there are uncertainties and that results and actual events may be implied. may differ materially from that expressed, implied or anticipated in any forward-looking information or statements. These risks and uncertainties include uncertainties related to the development of our products, which may not be successful, uncertainties related to marketing authorizations granted by competent authorities and, more generally, Includes factors that may affect your ability to market the products you develop. As developed or identified in public documents published by AB Science. AB Science disclaims any obligation or undertaking to update forward-looking information and statements pursuant to applicable regulations, in particular Sections 223-1 et seq. Provisions of the AMF General Regulations.
For more information, please contact us below.
AB Science
Financial communication and media relations
investors@ab-science.com
-
Webcast AB Science VEng VF
[ad_2]
Source link
